Manufacturing of Component by Fineblanking Technology

This bachelor thesis is focused on the design of production technology of the friction plate for the automatic gearbox DSG. Before selecting the most suitable technology for the production of friction plates the evaluation of different available technologies was carried out, of which as the most appropriate method, the accurate cutting with pressing edge was selected. The friction plate will be manufactured from metal sheet with the thickness of 1.5 mm, steel 12040, which will be supplied in coiled sheets. From the technological calculations followed that the friction plate will be produced in a one manufacturing operation. For serial production the machine HFA 3200 plus with the maximum force of 3200 kN was chosen. The main objective of the bachelor thesis is designing of cutting tools, creation of drawing documentation and technical - economic evaluation

Ethical aspects - problem of dying and death

The thesis is dealing with ethical aspects of the end of human existence. The first part of this work is focused on the issues of dying and death, especially in the understanding and development of death at the time. The process of dying, along with changes in the history of death brings with it certain ethical and moral issues that are further specified. Subsequently the thesis covers palliative care and its ethical principles. The final section presents an ethical problem and dilemmatic situations that workers in hospice facility may confront. It focuses on ethical decisions and actions of workers

Additional file 10: Table S8. of Identification of mRNA isoform switching in breast cancer

Significantly differentially expressed genes associated with the ratio of PRICKLE1 uc010skw.1 and uc001rnl.2. 1059 genes were identified by qualitative SAM analysis using a FDR of 0. And four gene signatures are enriched with cancer genes. (XLSX 89 kb

Additional file 5: Table S4. of Identification of mRNA isoform switching in breast cancer

List of 917 isoform switching pairs associated with significant up and down regulation in sample with low RIN scores. (XLSX 86 kb

Additional file 3: Table S3. of Identification of mRNA isoform switching in breast cancer

Functional annotation clustering of 43 genes with complex splicing patterns. Functional annotation clusters are sorted by the overall enrichment score based on the EASE score, a modified Fisher Exact P-value, of annotation terms. Genes associated with each term and the EASE Score are reported. Comparison of annotation terms associated with the top six clusters is coded as the following: Genes associated with specific terms are coded as 1; genes with no involvement are coded as 0. (XLSX 22 kb

Additional file 1: Table S1. of Identification of mRNA isoform switching in breast cancer

Patient characteristics of 728 breast tumors and 91 normal samples of TCGA BRCA dataset. (XLSX 54 kb

Additional file 1: Table S1. of Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study

Gene expression by participant and clinical characteristics from CBCS Phase 3, 2008–2013. Table S2. RNA counts overall and by race and estrogen receptor (ER) status from CBCS Phase 3, 2008–2013. Table S3. Gene expression and risk of recurrence among women with ER+/HER2– breast cancer from CBCS Phase 3, 2008–2013. (DOCX 81 kb

Additional file 2: of Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

Supplemental data. (XLSX 897 kb

Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy – results from two independent randomized trials

<p><b>Background:</b> The study of the intrinsic molecular subtypes of breast cancer has revealed differences among them in terms of prognosis and response to chemotherapy and endocrine therapy. However, the ability of intrinsic subtypes to predict benefit from adjuvant radiotherapy has only been examined in few studies.</p> <p><b>Methods:</b> Gene expression-based intrinsic subtyping was performed in 228 breast tumors collected from two independent post-mastectomy clinical trials (British Columbia and the Danish Breast Cancer Cooperative Group 82b trials), where pre-menopausal patients with node-positive disease were randomized to adjuvant radiotherapy or not. All patients received adjuvant chemotherapy and a subgroup of patients underwent ovarian ablation. Tumors were classified into intrinsic subtypes: Luminal A, Luminal B, HER2-enriched, Basal-like and Normal-like using the research-based PAM50 classifier.</p> <p><b>Results:</b> In the British Columbia study, patients treated with radiation had an overall significant lower incidence of locoregional recurrence compared to the controls. For Luminal A tumors the risk of loco-regional recurrence was low and was further lowered by adjuvant radiation. These findings were validated in the DBCG 82b study. The individual data from the two cohorts were merged, the hazard ratio (HR) for loco-regional recurrence associated with giving radiation was 0.34 (0.19 to 0.61) overall and 0.12 (0.03 to 0.52) for Luminal A tumors.</p> <p><b>Conclusions:</b> In both postmastectomy trials, patients with Luminal A tumors turned out to have a significant lower incidence of loco-regional recurrence when randomized to adjuvant radiotherapy, leaving no indication to omit postmastectomy adjuvant radiation in pre-menopausal high-risk patients with Luminal A tumors. It was not possible to evaluate the effect of radiotherapy among the other subtypes because of limited sample sizes.</p

Additional file 1: Table S1. of Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

Cox model DRFS analyses including intrinsic subtype in all patients from the MDACC-based cohort (GSE25066). Table S2. Cox model DRFS analyses including ROR-P in all patients from the MDACC-based cohort (GSE25066). Table S3. Cox model DRFS analyses including intrinsic subtype in patients that achieved a pCR from the MDACC-based cohort (GSE25066). Table S4. Cox model DRFS analyses including ROR-P in patients that achieved a pCR from the MDACC-based cohort (GSE25066). Table S5. Cox model DRFS analyses including ROR-P in patients with residual disease from the MDACC-based cohort (GSE25066). Table S6. Distribution of the PAM50 subtypes within the TNBCtype groups and vice versa. Table S7. Association of the TNBCtype subtypes with chemotherapy response in triple-negative breast cancer. Figure S1. CONSORT diagram of the various cohorts evaluated in this study. Figure S2. Kaplan-Meier distant relapse-free survival analysis in MDACC-based (GSE25066 [13]) dataset set. (A) Survival outcomes of the ROR-P groups in all patients. (B) Survival outcomes of the ROR-P groups in patients with clinically node-negative disease. Figure S3. Levels of ESR1 across TNBCtype ESR1-low group, TNBCtype ESR1-high group and ER+ group. Median expression of ESR1 in the PAM50 training dataset reported in Parker et al. [24] has been set to zero. Figure S4. Distribution of the TNBCtype subtypes and ESR1-high group within the PAM50 subtypes in TNBC. Figure S5. Distribution of the TNBCtype subtypes and ESR1-high group within the PAM50 + Claudin-low subtypes in TNBC. Figure S6. Training and testing gene expression-based models predictive of pCR in all patients. Figure S7. Training and testing gene expression-based models predictive of pCR in patients with Basal-like disease. Figure S8. Training and testing gene expression-based models predictive of pCR in patients with luminal (A/B) disease. (DOCX 819 kb